Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 96.71%
March 31, 2026 96.73%
December 31, 2025 95.58%
September 30, 2025 96.89%
June 30, 2025 96.57%
March 31, 2025 96.55%
December 31, 2024 96.48%
September 30, 2024 96.79%
June 30, 2024 97.23%
March 31, 2024 95.00%
December 31, 2023 95.46%
September 30, 2023 96.02%
June 30, 2023 96.23%
March 31, 2023 96.50%
December 31, 2022 96.24%
September 30, 2022 96.28%
June 30, 2022 96.79%
March 31, 2022 96.29%
December 31, 2021 97.14%
September 30, 2021 96.38%
June 30, 2021 96.14%
March 31, 2021 95.12%
December 31, 2020 96.65%
September 30, 2020 96.22%
June 30, 2020 96.45%
Date Value
March 31, 2020 95.91%
December 31, 2019 95.62%
September 30, 2019 97.23%
June 30, 2019 96.86%
March 31, 2019 96.52%
December 31, 2018 96.78%
September 30, 2018 96.73%
June 30, 2018 96.78%
March 31, 2018 97.34%
December 31, 2017 96.51%
September 30, 2017 96.95%
June 30, 2017 96.96%
March 31, 2017 96.04%
December 31, 2016 97.61%
September 30, 2016 96.05%
June 30, 2016 95.70%
March 31, 2016 95.56%
December 31, 2015 89.71%
September 30, 2015 81.74%
June 30, 2015 86.57%
March 31, 2015 88.68%
December 31, 2014 90.70%
September 30, 2014 60.36%
June 30, 2014 83.66%
March 31, 2014 83.55%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 76.88%
BioMarin Pharmaceutical, Inc. 72.27%
Cytokinetics, Inc. 67.78%
Emergent BioSolutions, Inc. 51.22%
Gilead Sciences, Inc. 79.81%

Gross Profit Margin (Quarterly) Related Metrics